Animal Model Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Animal Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Others), By Application (Cancer, Immunological Disease, Infectious Disease, Others), By Distribution Channel (Pharmaceutical & Biotechnology Companies, Academic Research Institute, Contract Research Organization) By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Animal Model Market is projected to grow substantially from USD 1.97 billion in 2025 to USD 3.22 billion by 2031, exhibiting an 8.53% compound annual growth rate. These non-human organisms, including rodents, primates, and zebrafish, are crucial for scientific research, replicating human biological systems and disease pathologies to develop medical interventions. Market expansion is primarily driven by the escalating prevalence of chronic and infectious diseases necessitating extensive preclinical testing, coupled with stringent regulatory mandates requiring comprehensive safety and toxicity assessments prior to human clinical trials. Further bolstering this growth is the increasing research and development (R&D) expenditure by pharmaceutical and biotechnology companies, with global drugmakers investing nearly $288 billion in R&D in 2024, as reported by BioSpace in May 2025. This significant investment ensures a steady demand for in vivo systems, a fact underscored by Charles River Laboratories' 2024 revenue of $4.05 billion. Government funding also plays a vital role, exemplified by the National Institutes of Health (NIH) receiving $46.995 billion for FY2025, which provides essential support for academic and public research.
However, the market faces a significant challenge due to escalating ethical scrutiny and stringent international regulations on animal welfare, which increasingly promote the '3Rs' principles—Replacement, Reduction, and Refinement. These pressures lead to higher compliance costs and longer approval times for in vivo studies, redirecting research budgets towards non-animal testing methods and resulting in reduced animal usage, such as the UK's drop to approximately 77% of 2019 levels by 2025 according to the UK Bioscience Sector Coalition. Concurrently, the sector is being reshaped by key trends. The accelerated adoption of humanized immune system models is enhancing translatability, especially in immuno-oncology, with Biocytogen executing around 200 therapeutic antibody co-development and licensing agreements for its RenMice platforms by late 2024. Additionally, there's a strategic shift towards outsourcing model generation to Contract Research Organizations (CROs), driven by the complexity and cost of maintaining genetic lines in-house. This outsourcing trend is evident in Charles River Laboratories' Research Models and Services segment generating $829.4 million in annual revenue in 2024, reflecting sustained industry reliance on specialized external providers.
Market Driver
The market's growth is predominantly fueled by the increasing research and development (R&D) investments from pharmaceutical and biotechnology companies, which demand robust preclinical validation using in vivo systems for novel therapeutics. This financial commitment ensures a consistent supply chain for various animal species used in toxicology and efficacy studies. For instance, drugmakers globally invested nearly $288 billion in R&D in 2024, as noted by BioSpace in May 2025, underscoring the reliance on animal models. The sector also benefits from a surge in government funding for biomedical research, providing essential liquidity for academic and public institutions that extensively utilize genetically modified and disease-specific models. The National Institutes of Health (NIH), for example, received $46.995 billion for fiscal year 2025, according to Congress.gov in December 2025, which acts as a stabilizing force, ensuring continuous demand for biological tools in grant-funded studies.
Market Challenge
A significant impediment to the Global Animal Model Market's expansion stems from stringent international regulations concerning animal welfare and intensifying ethical scrutiny. These regulatory frameworks increasingly enforce the '3Rs' principles—Replacement, Reduction, and Refinement—mandating a systematic decrease in live animal use for scientific experimentation. This environment compels pharmaceutical and biotechnology entities to face higher compliance costs and prolonged approval timelines for in vivo studies, consequently discouraging the procurement of animal models. This redirection of research budgets toward compliance and alternative testing methods has led to reduced transaction volumes, with scientific procedures involving animals in the UK dropping to approximately 77% of 2019 levels by 2025, as reported by the UK Bioscience Sector Coalition, thereby dampening revenue potential.
Market Trends
The market is undergoing transformative shifts, notably with the accelerated adoption of humanized immune system models. These advanced biological systems are becoming vital for improving the translatability of preclinical studies to human clinical outcomes, particularly in immuno-oncology, by replacing murine immune components with functional human counterparts. This trend is quantitatively demonstrated by Biocytogen's execution of approximately 200 therapeutic antibody co-development and licensing agreements for its RenMice humanized model platforms by the end of 2024, as per their June 2025 press release. Additionally, a strategic shift towards outsourcing model generation to Contract Research Organizations (CROs) is evident. This move, driven by the increasing complexity and cost of maintaining sophisticated genetic lines in-house, allows pharmaceutical developers to convert fixed infrastructure costs into variable service expenditures while leveraging specialized technical expertise. Charles River Laboratories' Research Models and Services (RMS) segment, which generated $829.4 million in annual revenue in 2024, as reported in February 2025, exemplifies the industry's sustained reliance on outsourced model management and production capabilities.
Key Market Players
* Charles River Laboratories International Inc.
* The Jackson Laboratory
* Taconic Biosciences, Inc.
* Janvier Labs S.A.S.
* HBM Holdings Limited
* Crown Bioscience Inc.
* Inotiv Inc.
* Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
* BioSpherix, Ltd
Report Scope
In this report, the Global Animal Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Animal Model Market, By Animal Type
* Mice
* Rat
* Guinea Pigs
* Rabbits
* Hamsters
* Others
# Animal Model Market, By Application
* Cancer
* Immunological Disease
* Infectious Disease
* Others
# Animal Model Market, By Distribution Channel
* Pharmaceutical & Biotechnology Companies
* Academic Research Institute
* Contract Research Organization
# Animal Model Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Animal Model Market.
Available Customizations:
Global Animal Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Animal Model Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Animal Type (Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Others)
5.2.2. By Application (Cancer, Immunological Disease, Infectious Disease, Others)
5.2.3. By Distribution Channel (Pharmaceutical & Biotechnology Companies, Academic Research Institute, Contract Research Organization)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Animal Model Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Animal Type
6.2.2. By Application
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Animal Model Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Animal Type
6.3.1.2.2. By Application
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Animal Model Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Animal Type
6.3.2.2.2. By Application
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Animal Model Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Animal Type
6.3.3.2.2. By Application
6.3.3.2.3. By Distribution Channel
7. Europe Animal Model Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Animal Type
7.2.2. By Application
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Animal Model Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Animal Type
7.3.1.2.2. By Application
7.3.1.2.3. By Distribution Channel
7.3.2. France Animal Model Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Animal Type
7.3.2.2.2. By Application
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Animal Model Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Animal Type
7.3.3.2.2. By Application
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Animal Model Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Animal Type
7.3.4.2.2. By Application
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Animal Model Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Animal Type
7.3.5.2.2. By Application
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Animal Model Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Animal Type
8.2.2. By Application
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Animal Model Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Animal Type
8.3.1.2.2. By Application
8.3.1.2.3. By Distribution Channel
8.3.2. India Animal Model Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Animal Type
8.3.2.2.2. By Application
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Animal Model Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Animal Type
8.3.3.2.2. By Application
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Animal Model Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Animal Type
8.3.4.2.2. By Application
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Animal Model Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Animal Type
8.3.5.2.2. By Application
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Animal Model Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Animal Type
9.2.2. By Application
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Animal Model Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Animal Type
9.3.1.2.2. By Application
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Animal Model Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Animal Type
9.3.2.2.2. By Application
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Animal Model Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Animal Type
9.3.3.2.2. By Application
9.3.3.2.3. By Distribution Channel
10. South America Animal Model Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Animal Type
10.2.2. By Application
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Animal Model Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Animal Type
10.3.1.2.2. By Application
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Animal Model Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Animal Type
10.3.2.2.2. By Application
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Animal Model Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Animal Type
10.3.3.2.2. By Application
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Animal Model Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Charles River Laboratories International Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. The Jackson Laboratory
15.3. Taconic Biosciences, Inc.
15.4. Janvier Labs S.A.S.
15.5. HBM Holdings Limited
15.6. Crown Bioscience Inc.
15.7. Inotiv Inc.
15.8. Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
15.9. BioSpherix, Ltd
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們